Drug Trial Radar · NCT02838225
DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jan 2009
Primary completion
Jan 2016
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
Conditions
- Breast Cancer
Interventions
Docetaxel, DoxorubicinDrug
Docetaxel, Doxorubicin, CyclophosphamideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survivalTime frame: 5 years
- Adverse event rate (CTCAE v. 3.0)Time frame: 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.